30 articles - From Friday Aug 05 2022 to Friday Aug 12 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Am J Kidney Dis |
Effect of Long-term Exercise Training on Physical Performance and Cardiorespiratory Function in Adults With CKD: A Randomized Controlled Trial. Among adults =55 years with CKD stages G3b-4 and a high level of medical comorbidity, a 12-month program of in-center aerobic and resistance exercise training was safe and associated with improvements in physical functioning. |
Proliferative Glomerulonephritis With Hidden Monotypic IgG3 We demonstrate, using several ancillary techniques including the newly described antibodies directed against the conformational epitope at the junctions of heavy and light chains (HLC-IF), that the first biopsy likely represents IgG3 |
Psychosocial Distress in Patients With Advanced CKD by Racial Group and Immigrant Status: A Canadian Cross-sectional Study. Both racialized and immigrant status based on self-report of demographic characteristics were associated with psychosocial distress among patients with advanced CKD. These patients may benefit from culturally competent psychosocial support. |
| Clin J Am Soc Nephrol |
Incidence and Risk Factors for Dialysis Reinitiation among Patients with a History of Dialysis Dependency. Age at first dialysis, cause of kidney disease, history of CKD or nephrology care prior to starting dialysis, presence of heart failure, CKD stage following recovery of kidney function, and location of first dialysis initiation (inpatient versus outpatient) were some of the risk factors that were strongly associated with the risk of restarting dialysis after the recovery of kidney function. Over one in five patients with recovery of kidney function after kidney failure restarted dialysis within 3 years. |
| J Am Soc Nephrol |
| Kidney Int |
Angiopoietin-2 inhibition attenuates kidney fibrosis by hindering chemokine C-C motif ligand 2 expression and apoptosis of endothelial cells. Based on this, we applied L1-10, an angiopoietin-2 inhibitor, to the mouse models of progressive kidney disease and found inhibitory effects on macrophage infiltration, microvascular rarefaction, and fibrosis. Thus, we defined the detrimental impact of increased angiopoietin-2 on kidney survival of patients with CKD which appears highlighted by angiopoietin-2 induced endothelial CCL2-activated macrophage infiltration and endothelial cell apoptosis in their kidneys undergoing fibrosis. |
Cellular communication network 2 (connective tissue growth factor) aggravates acute DNA damage and subsequent DNA damage response-senescence-fibrosis following kidney ischemia reperfusion injury. Thus, our observations indicate that inhibition of CCN2 can mitigate IRI-induced acute kidney injury, DNA damage, and the subsequent DDR-senescence-fibrosis sequence. Hence, targeting CCN2 might help to protect the kidney from transplantation associated post-IRI chronic kidney dysfunction. |
Persistent DNA damage underlies tubular cell polyploidization and progression to chronic kidney disease in kidneys deficient in the DNA repair protein FAN1. Thus, our data delineate a mechanistic pathway by which persistent DNA damage in the kidney tubular cells leads to kidney injury and development of CKD. Furthermore, therapeutic modulation of cell cycle activity may provide an opportunity to mitigate the DNA damage response induced CKD progression. |
| Nephrol Dial Transplant |
Impact of different COVID-19 waves on kidney replacement therapy epidemiology and mortality: REMER 2020. COVID-19 negatively impacted the incidence and prevalence of KRT, but the increase in KRT deaths was localized to the first wave of the pandemic. The increased annual mortality argues against COVID-19 accelerating death of patients with short life expectancy and the temporal pattern of COVID-19 mortality suggests that appropriate healthcare may improve outcomes. |
Quantifying the benefits of remission duration in focal and segmental glomerulosclerosis. In FSGS, unless remissions are maintained and relapses avoided, long-term renal survival remains poor. Treatment strategies addressing remission duration remain poorly defined and should be an essential question in future trials. |
Tacrolimus induces a pro-fibrotic response in donor-derived human proximal tubule cells dependent on common variants of CYP3A5 and ABCB1 genes. Tacrolimus exposure induces a pro-fibrotic response in a PTC model in function of the donor pharmacogenetic background associated with tacrolimus metabolism. These finding provide a mechanistic insight in the nephrotoxicity associated with tacrolimus treatment and offers opportunities for a tailored immunosuppressive treatment. |
Targeted nanotherapy for kidney diseases: a comprehensive review. However, some limitations have slowed the transition of these agents from pre-clinical studies to clinical trials. In this review, we summarize the current knowledge on renal drug delivery systems and recent advances in renal cell targeting, and we demonstrate their important potential as future paradigm-shifting therapies for kidney diseases. |
Urinary extracellular vesicles and tubular transport. Although uEVs hold the promise to advance the diagnosis of kidney disease to the molecular level, several biological and technical complexities still need to be addressed. The future will tell if uEV analysis will mainly be a powerful tool to study tubular physiology in humans or if it will move forward to become a diagnostic bedside test. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Am J Kidney Dis |
| Clin J Am Soc Nephrol |
| J Am Soc Nephrol |
| Nat Rev Nephrol |
Letters to the editors and authors’ replies
| Am J Kidney Dis |
| Clin J Am Soc Nephrol |
| J Am Soc Nephrol |
all remaining publications eg case reports, images of the month, etc…
| J Am Soc Nephrol |
| Nat Rev Nephrol |